CytomX Therapeutics, Inc. (CTMX)

Market Cap	950.53M
Revenue (ttm)	113.63M -10.3%
Net Income	28.02M +102.6%
EPS	0.24 +50.2%
Shares Out	169.44M
PE Ratio	23.04
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,229,430
Open	5.30
Previous Close	5.34
Day's Range	5.30 - 5.52
52-Week Range	0.40 - 6.15
Beta	2.42
Analysts	Strong Buy
Price Target	8.00 (+42.6%)
Earnings Date	Mar 5, 2026

About CTMX

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBO...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 8, 2015
• Employees: 121
• Stock Exchange: NASDAQ
• Ticker Symbol: CTMX
• Website: https://www.cytomx.com

Analyst Summary

According to 7 analysts, the average rating for CTMX stock is "Strong Buy." The 12-month stock price target is $8.0, which is an increase of 42.60% from the latest price.

Price Target

$8.0

(42.60% upside)

Analyst Consensus: Strong Buy